Department of Gynecology and Obstetrics, University Hospital of Würzburg; AWMF-Institute for Medical Knowledge Management, c/o Philipps Universität Marburg; Department of Obstetrics and Gynaecology, Ulm University; Frauenklinik St. Marien, Amberg.
Dtsch Arztebl Int. 2018 May 4;115(18):316-323. doi: 10.3238/arztebl.2018.0316.
Breast cancer is the most common cancer in women. The German S3 guideline of 2012 has now been updated to take account of advances in the early detection, diagnostic evaluation, treatment, and follow-up care of this disease.
The updating process was based on the adaptation of identified source guidelines and on reviews of the scientific evidence. A systematic search in multiple literature databases was carried out, and the full texts of the selected articles were evaluated. Suggested recommendations were then proposed by interdisciplinary working groups and modified and graded in a nominal consensus procedure.
The value of mammographic screening is confirmed in the updated guideline. As for the diagnostic evaluation of breast cancer, computed tomography is recommended for staging in patients with a high risk of recurrence, in addition to conventional methods. As for surgical treatment, the evidence supporting locoregional surgery for primary breast cancer now affords an opportunity for de-escalation: complete resection yields the best outcome, but a safety margin of several millimeters is not necessary. Axillary dissection is no longer recommended except in certain defined situations. Radiotherapeutic approaches consist of hypofractionated applications. Adjuvant systemic therapy is indicated for patients in certain high-risk situations defined by a constellation of factors including tumor grade, patient age, node status, Ki-67 antigen expression, hormone receptor status, and human epidermal growth factor receptor 2 (HER2) status. All patients with hormone receptor-positive breast cancer should receive endocrine therapy. The indication for chemotherapy and/or anti-HER2 therapy should be determined in consideration of the expected benefit and side effects.
Consistent implementation of the recommendations in the newly updated guideline can help lessen morbidity and mortality from breast cancer. The actual extent to which breast cancer guidelines are implemented should be a topic of future research.
乳腺癌是女性最常见的癌症。2012 年德国 S3 指南现已更新,以纳入该疾病的早期发现、诊断评估、治疗和随访护理方面的进展。
更新过程基于对已确定的源指南的改编以及对科学证据的审查。在多个文献数据库中进行了系统搜索,并评估了选定文章的全文。然后,跨学科工作组提出了建议建议,并在名义共识程序中进行了修改和分级。
更新指南中证实了乳腺筛查的价值。对于乳腺癌的诊断评估,除了常规方法外,对于复发风险高的患者,建议进行计算机断层扫描分期。对于手术治疗,目前支持原发性乳腺癌局部区域手术的证据为降级提供了机会:完全切除可获得最佳结果,但不需要几毫米的安全裕度。除非在某些明确的情况下,否则不再推荐腋窝清扫。放射治疗方法包括分次应用。对于某些高危情况的患者,包括肿瘤分级、患者年龄、淋巴结状态、Ki-67 抗原表达、激素受体状态和人表皮生长因子受体 2(HER2)状态等因素组合定义,建议进行辅助全身治疗。所有激素受体阳性乳腺癌患者均应接受内分泌治疗。应考虑预期益处和副作用来确定化疗和/或抗 HER2 治疗的指征。
一致实施新更新指南中的建议有助于降低乳腺癌的发病率和死亡率。未来的研究应关注乳腺癌指南的实际实施程度。